Swaziland is one of three remaining countries in the Southern Africa Development Community Region that do not have adequate regulatory and legislative frameworks to control the use, importation, manufacturing, and exportation of medicines. This is in the face of increased incidence of counterfeit medicines in the region; up to 25% of marketed medicines are substandard, … Read more
Swaziland’s Ministry of Health has published its Pharmaceutical Strategic Plan, 2012-2016, serving as a roadmap for the revised national pharmaceutical policy. This report is intended to facilitate the monitoring and evaluation of implementation of the Strategic Plan. The report is a reflection of characteristics of the pharmaceutical sector in 2012.
The DGDA invited the USAID-funded SIAPS program to provide support for a comprehensive assessment of the Bangladeshi pharmaceutical regulatory system. The SIAPS program used the Regulatory Systems Assessment Tool (RSAT) to conduct a structured assessment of the DGDA, reviewed more than 50 documents, and conducted interviews with key informants. The assessment also reviewed the DGDA’s … Read more
Download Access to medicines remains a major issue for the Haitian population. National-level statistics show that less than half the population has acceptable access to medicines. In addition, for those who have access, there is no guarantee of the quality of medicines. As part of the strategy to reform the health system, the MSPP has … Read more
